Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

BACKGROUND: Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases. Calcitonin gene-related peptide monoclonal antibodies are a relatively novel molecular treatment for episodic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Troy, Emma, Shrukalla, Arif A., Buture, Alina, Conaty, Katie, Macken, Esther, Lonergan, Roisin, Melling, Jane, Long, Niamh, Shaikh, Eamonn, Birrane, Kieran, Tomkins, Esther M., Goadsby, Peter J., Ruttledge, Martin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841480/
https://www.ncbi.nlm.nih.gov/pubmed/36647006
http://dx.doi.org/10.1186/s10194-022-01536-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841480/
https://www.ncbi.nlm.nih.gov/pubmed/36647006
http://dx.doi.org/10.1186/s10194-022-01536-3

Ejemplares similares